MRD-associated Non-intensive But Non-interruptive Treatment of Ph-negative Acute Lymphoblastic Leukemia Adult Patients

Launched by NATIONAL RESEARCH CENTER FOR HEMATOLOGY, RUSSIA · Jan 31, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for adults with a type of blood cancer called Ph-negative acute lymphoblastic leukemia (ALL). The goal is to find out if a non-intensive treatment plan can effectively manage the disease without using high doses of certain strong chemotherapy drugs. Participants in the trial will receive a year-long treatment that includes a specific medication called L-asparaginase and several injections to deliver medicine directly into the spinal fluid. Depending on the type of ALL they have and their response to earlier treatments, some patients may also receive additional medications to help achieve a better response.

To be eligible for this trial, participants must be between 18 and 55 years old and have a clinical diagnosis of untreated Ph-negative ALL. Unfortunately, those over 55, those with a different type of ALL known as Ph-positive, or those whose disease has come back after treatment cannot participate. Throughout the trial, patients will be monitored closely, and if they reach a certain level of remission, they may continue with the treatment plan without needing a stem cell transplant. This trial is currently recruiting participants, and it offers a chance to explore a treatment that might improve outcomes for adults facing this challenging cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • • age 18-55 years old of patient,
• • - Clinical diagnosis of non-treated Ph-negative ALL
• Exclusion Criteria:
• • • age more than 55 years old,
• • Clinical diagnosis of Ph-positive ALL
• • Clinical diagnosis of relapsed/refractory ALL,